The type II IFNs, including IFN-γ can be released by CD8+ T and Th1 cells to induce a number of cells, including NK cells, M1 macrophages, and CD8+ T cells for enhancing MHC I and II presentation, promoting the anti-cancer immunity [203]. Here, CD8A is linked to cancer.